DIM
FDA status: We found no FDA-approved drug product listing dim as an active ingredient in openFDA.
PubMed: 706 publications mention DIM, 12 of them trials or reviews. Search PubMed
- Systemic Review of Clot Retraction Modulators. Guilbeau A et al. International journal of molecular sciences, 2023. Systematic Review. PMID 37445780 · DOI
- A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Thomson CA et al. Breast cancer research and treatment, 2017. Randomized Controlled Trial. PMID 28560655 · DOI
- Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. Gee JR et al. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2016. Clinical Trial, Phase I, Randomized Controlled Trial. PMID 26313229 · DOI
- Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. Del Priore G et al. Gynecologic oncology, 2010. Clinical Trial, Phase III, Randomized Controlled Trial. PMID 19939441 · DOI
- Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3'-diindolylmethane in healthy subjects. Reed GA et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2008. Randomized Controlled Trial. PMID 18843002 · DOI
ClinicalTrials.gov: 21 registered studies. See all studies
- NCT01612910 Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery (Phase 2), withdrawn
- NCT01022333 The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers (Phase 1), unknown









